OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the
treatment of patients with metastatic renal cell carcinoma. This trial will be one of the
first phase II trials to evaluate a combination of targeted agents in the treatment of a
common solid tumor with a strong biologic rationale based on Cancer Biology
(VHL/HIF/VEGF/EGFr).